Key facts
- It has raised $28.9M across 1 recorded rounds; the latest was Early Stage VC ($13.8M) in Dec 2022.
- Notable investors include Y Combinator, General Catalyst, Microsoft for Startups, Nexus Venture Partners, Lightspeed India Partners — 9 tracked in total.
- Triomics has filed 1 Form D with the SEC, most recently Feb 2023 ($13.8M sold to 10 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Triomics
Funding rounds
1 roundsAbout Triomics
Developer of an interconnectivity and workflow automation platform intended to accelerate clinical trials. The company's platform eliminates the operational inefficiencies in data collection, patient recruitment and other laborious tasks involved in clinical research, enabling pharmaceutical companies and contract research organizations to deliver rapid, cost-effective, optimal clinical trials.
- Sector
- Information Technology
- HQ
- San Francisco, CA, United States
- Founded
- 2020
- Employees
- 55
- Website
- triomics.com/
- Ownership
- Privately Held (backing)
Triomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Triomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Triomics in its N-PORT filings yet. We sweep new filings monthly.